期刊文献+

围术期质子泵抑制剂质控模式的建立及效果 被引量:1

Quality control model of perioperative proton pump inhibitor:establishment and effect
下载PDF
导出
摘要 目的建立围术期质子泵抑制剂(PPI)质控模式,并评价其应用效果。方法通过“处方前置审核、病历点评、PDCA循环法及行政辅助”的四维管理,建立围术期PPI的质控模式。分析实施质控后围术期PPI问题医嘱数量及不合理用药类型的变化。结果2019年7~12月期间,围术期PPI的医嘱从1230条减少至766条,下降37.72%;提示医嘱从717条减少至316条,下降55.93%;临床医生对问题医嘱主动修改率从17.71%(127/717)提高到33.54%(106/316),问题医嘱占比从47.97%(590/1230)下降至27.42%(210/766);围术期PPI不合理用药病历从7月的98份下降到12月的35份,下降幅度为64.29%;不合理用药类型主要为预防用药不适宜及给药途径不适宜。结论通过建立有效的围术期PPI质控模式,对其持续循环改进,加强医学与药学不同知识领域的相互补充,利用医学信息化数据的管理和支持,能更好地促进围术期PPI合理用药。 Objective To establish the quality control model of perioperative proton pump inhibitor(PPI),and to assess its application effect.Methods Through the four-dimensional management of"prescription pre-audit,medical record review,PDCA cycle method and administrative assistance",the quality control model of perioperative PPI was established.Changes in the number of defective physician orders and the category of non-rational use of drug involving PPI during perioperative period were analyzed after the implementation of quality control.Results From July to December,2019,the number of perioperative physician orders involving PPI dropped from 1230 to 766 by 37.72%;the number of prompt orders dropped from 717 to 316 by 55.93%;in clinicians the proactive modification rate of defective physician orders increased from 17.71%(127/717)to 33.54%(106/316),and the proportion of defective physician orders decreased from 47.97%(590/1230)to 27.42%(210/766);the number of medical records concerning perioperative non-rational use of PPI dropped from 98 copies in July to 35 copies in November,with a decrease rate of 64.29%.The majority of non-rational use of drug was unadvisable prophylactics and unadvisable medication approaches.Conclusion Promoting perioperative rational use of PPI preferably is achieved by establishing a model of effective perioperative PPI quality control,carrying out continuous cycle improvement,strengthening the mutual complementation of different knowledge areas of medicine and pharmacy,and utilizing the management and support of medical information data.
作者 朱宇欢 区家茵 曹强 李爱平 唐卫 ZHU Yu-huan;OU Jia-yin;CAO Qiang;LI Ai-ping;TANG Wei(Department of Pharmacy,Yongwu Hospital of the People′s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530001,China)
出处 《广西医学》 CAS 2021年第4期447-450,共4页 Guangxi Medical Journal
基金 广西医药卫生科研课题(Z20200193)。
关键词 质子泵抑制剂 围术期用药 质控模式 处方前置审核 PDCA循环法 管理 合理用药 Proton pump inhibitor Perioperative medication Quality control model Prescription pre-audit PDCA cycle method Management Rational use of drug
  • 相关文献

参考文献10

二级参考文献87

  • 1郑英键.应激性溃疡[J].医学新知,2006,16(1):10-11. 被引量:32
  • 2李兆申.重视应激性溃疡的规范化防治[J].世界华人消化杂志,2005,13(22):2637-2639. 被引量:88
  • 3中华医学杂志编辑委员会.应激性溃疡防治建议[J].中华医学杂志,2002,82:1000-1001.
  • 4Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient [ J 1. Nat Rev Gastroenterol Hepatol, 2015, 12(2) :9$-107.
  • 5Quenot JP, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? [J]. Curr Opin Crit Care, 2009, 15(2) :139-143.
  • 6Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group[J~. N Engl J Med, 1994, 330(6) :377-381.
  • 7Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients [ J ]. J Crit Care, 2005, 20 (1) :35-45.
  • 8ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998 [ J]. Am J Health Syst Pharm, 1999, 56(4) :347-379.
  • 9Spirt M J, Stanley S. Update on stress ulcer prophylaxis in critically ill patients [ J ]. Crit Care Nurse, 2006, 26 ( 1 ) : 18-20, 22 -25.
  • 10Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the new millennium : a systematic review and meta-analysis [ J ]. Crit Care Med, 2010, 38 ( 11 ) :2222-2228.

共引文献503

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部